IP Library Granted Patent US 7,973,154
Granted Patent B2
US 7,973,154 · App. 11/137,935 · Granted Jul 5, 2011

Kits for diagnosis and monitoring of viral infection by analysis of viral transrenal nucleic acids in urine

Assignee: TrovaGene, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,973,154
App. No.
11/137,935
Granted
Jul 5, 2011
Kind
B2
Abstract

The present invention relates to methods for diagnosis or monitoring of viral infection by detecting the presence of transrenal viral nucleic acids or nucleic acids of viral origin in urine sample, with or without isolation of nucleic acids from a urine sample. The analysis of the nucleic acids is performed through hybridization of the nucleic acids with specific probes, or through a chain amplification reaction with specific primers. The methods are applicable to all viral pathogenic agents, including RNA, DNA, episomal, or integrated viruses.

Claims (15)

1. A kit, comprising:

a) two or more reagents or materials for isolation and purification of cell-free nucleic acids of a virus from a urine sample of a subject, wherein said reagents or materials comprise a matrix including a silica-based resin, wherein said silica-based resin isolates nucleic acids that are less than 300 nucleotides and wherein said reagents or materials comprise an agent that inhibits the degradation of said cell-free nucleic acids; and

b) two or more primers for detecting said cell-free nucleic acids of a virus in said urine sample, wherein the two or more primers comprise a forward primer consisting of SEQ ID NO: 5 and a reverse primer that is selected from the group consisting of SEQ ID NOs: 6-8.

2. The kit according to claim 1 , further comprising reagents for performance of a technique selected from the group consisting of hybridization of nucleic acids, cycling probe reaction, polymerase chain reaction, nested polymerase chain reaction, ligase chain reaction, and strand displacement amplification,

3. The kit according to claim 2 , further comprising primers that are specific for nucleic acids that encode a viral agent.

4. The kit according to claim 1 , further comprising a chaotropic agent.

5. The kit according to claim 1 , further comprising agents selected from the group consisting of ion-chelating agents, denaturing agents, and ionic detergents.

6. The kit according to claim 5 , wherein said ion-chelating agent is EDTA; said denaturing agent is selected from the group consisting of guanidine HC 1 and guanidine isothiocyanate; or said ionic detergent is selected from the group consisting of N-lauryl sarcosine and sodium dodecyl sulfate.

7. A kit comprising:

a) two or more reagents or materials for the detection and quantitation of cell-free nucleic acids of a virus from a urine sample of a subject, wherein said reagents or materials comprise a matrix including a silica-based resin, wherein said silica-based resin isolates nucleic acids that are less than 300 nucleotides and wherein said reagents or materials comprise an agent that inhibits the degradation of said cell-free nucleic acids in urine; and

b) two or more primers for detecting and quantitating said cell-free nucleic acids of a virus in said urine sample, wherein the two or more primers comprise a forward primer consisting of SEQ ID NO: 5 and a reverse primer that is selected from the group consisting of SEQ ID NOs: 6-8.

8. The kit according to claim 7 further comprising reagents for performance of a technique selected from the group consisting of hybridization of the nucleic acids, cycling probe reaction, polymerase chain reaction, nested polymerase chain reaction, ligase chain reaction, and strand displacement amplification.

9. The kit according to claim 7 , further comprising a chaotropic agent.

10. The kit according to claim 7 , wherein said agents are selected from the group consisting of ion-chelating agents, denaturing agents, and ionic detergents.

11. The kit according to claim 10 , wherein said ion-chelating agent is EDTA; said denaturing agent is selected from the group consisting of guanidine HCl and guanidine isothiocyanate; or said ionic detergent is selected from the group consisting of N-lauryl sarcosine and sodium dodecyl sulfate.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 9, 2010
From: NATIONAL INSTITUTE OF INFECTIOUS DISEASES LAZZARO SPALLANZANI
To: XENOMICS, INC.
Reel/Frame 024809/0001 →
MERGER Recorded Aug 9, 2010
From: XENOMICS, INC.
To: TROVAGENE, INC.
Reel/Frame 024809/0079 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 1, 2005
From: MELKONYAN, HOVSEP; UMANSKY, SAMUIL R.; CANNAS, ANGELA; TOMEI, LOUIS DAVID
To: INSTITUTO NAZIONALE PER LE MALATTIE INFETTIVE IRCCS LAZZARO SPALLANZANI
Reel/Frame 016831/0469 →
Priority Claims (1)
IT RM2005A0067 · Feb 17, 2005 · national
Continuity (1)
Related Publication 20060183108A1 · Aug 17, 2006